What is Mimetas?
Mimetas operates at the intersection of microfluidics, 3D tissue biology, and advanced data analytics. The company specializes in developing sophisticated organ-on-a-chip systems that simulate human physiological responses with unprecedented accuracy. By creating human-relevant tissue models, Mimetas enables biotechnology and pharmaceutical organizations to conduct more predictive drug discovery and safety assessments. This approach significantly reduces the reliance on traditional animal models, offering a more ethical and efficient pathway for evaluating drug efficacy and disease biology in a controlled, high-throughput environment.
How much funding has Mimetas raised?
Mimetas has raised a total of $6.8M across 2 funding rounds:
Unspecified
$1.6M
Unspecified
$5.2M
Unspecified (2014): $1.6M, investors not publicly disclosed
Unspecified (2014): $5.2M led by Participatiemaatschappij Oost Nederland NV and Zeeuws InvesterinsFonds
Key Investors in Mimetas
Participatiemaatschappij Oost Nederland NV
PPM Oost is a public venture capital firm based in the Netherlands that supports regional economic leaders in sectors such as Life Sciences and High-tech Materials.
Zeeuws InvesteringsFonds
Zeeuws InvesteringsFonds provides strategic capital and operational support to high-potential businesses, focusing on fostering growth and innovation within the Zeeland region.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Mimetas?
Looking ahead, the recent capital influx is expected to accelerate the commercial deployment of Mimetas' platform across global pharmaceutical pipelines. As the industry shifts toward more predictive, human-centric testing methodologies, Mimetas is poised to expand its footprint in the preclinical research market. Strategic priorities likely include the scaling of manufacturing capabilities for its organ-on-a-chip devices and the further integration of AI-driven analytics to enhance the predictive power of its tissue models. By maintaining its focus on high-impact research and development, the company is set to remain a cornerstone of modern drug discovery innovation.
See full Mimetas company page
